Serina Therapeutics shares rise 12.07% intraday as CEO to discuss FDA impacts on drug development timelines.

Serina Therapeutics surged 12.07% intraday after announcing its CEO, Steven Ledger, will host a webinar on February 4, 2026, titled “Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences.” The event, organized by Tribe Public LLC, will include a live Q&A session where Ledger will address potential impacts of FDA regulatory priorities on drug development timelines and review processes. The webinar’s focus on navigating FDA policies in 2026, coupled with direct investor engagement through a complimentary registration and Q&A, likely boosted market confidence in Serina’s ability to adapt to regulatory shifts. As a clinical-stage biotech firm, clarity on FDA expectations is critical for its pipeline progress, making the event a key catalyst for the intraday rally.